HCWB HCW Biologics (HCWB) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001828673
Cluster · 4 insidersC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter
What the filings say about HCWB
Insiders, 180 days
+$531.5K net bought
4 buyers
HCW Biologics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, HCW Biologics Inc. insiders bought a net $531.5K of stock across 89 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on May 22, 2026.
- -47.0% median (-54.7% mean) 90-day return after 4 previous buys.
- The trade is 18.6% of the 41,644 shares held after it.
- 2 other insiders bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GARRETT SCOTT T bought about $20.0K of HCWB on Jul 29, 2026; 2 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on May 8, 2025.
- -31.0% median (-30.5% mean) 90-day return after 6 previous buys.
- The trade is 89.0% of the 8,691 shares held after it.
- 2 other insiders bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP of Business Development Flowers Lee bought about $20.0K of HCWB on Jul 29, 2026; 2 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 buys), the last on May 22, 2026.
- -23.4% median (-14.7% mean) 90-day return after 20 previous buys.
- The trade is 18.4% of the 125,845 shares held after it.
- 2 other insiders bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Wong Hing C bought about $60.0K of HCWB on Jul 29, 2026; 2 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 buys), the last on May 16, 2025.
- -22.7% median (-10.9% mean) 90-day return after 19 previous buys.
- The trade is 18.5% of the 615,790 shares held after it.
- 2 other insiders bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Wong Hing C bought about $160.6K of HCWB on May 22, 2026, the largest insider purchase at the company since 2025; 2 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on May 16, 2025.
- -42.6% median (-43.6% mean) 90-day return after 3 previous buys.
- The trade is 87.5% of the 203,441 shares held after it.
- 2 other insiders bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GARRETT SCOTT T bought about $250.9K of HCWB on May 22, 2026, the largest insider purchase at the company since 2025; 2 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.89 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$531.5K over 180 days
+$220.6K of it by a 10%+ holder
more than 85% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
-97.9% year over year
below 91% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 65% of Pharma & Biotech
The situation: each line is one rule over one dataset
4 insiders independently bought a net $531.5K while the stock fell 58% over six months, with no planned sales queued.
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch HCWB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-95.3%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HCWB: institutional holders (13F)
13F holdings, latest reported quarter
52,138 sh
$260.2K
19,942 sh
$99.5K
6,510 sh
$32.5K
4,117 sh
$20.5K
$16.7K
Congress trades in HCWB
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HCWB planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HCWB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$63.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$10.0K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$816 position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$1.4K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $531.5K bought by insiders over 180 days, 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
HCWB financials
Revenue growth
-97.9%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HCWB
| FY Dec 2025 | $54.2K |
| FY Dec 2024 | $2.6M |
| FY Dec 2023 | $2.8M |
| FY Dec 2022 | $6.7M |
| FY Dec 2021 | $0 |
| Jun 2026 | $135.6K |
| Mar 2026 | $6.5M |
| Dec 2025 | $27.0K |
| Sep 2025 | $15.6K |
| Jun 2025 | $6.5K |
| Mar 2025 | $5.1K |
| Dec 2024 | $394.8K |
| Sep 2024 | $426.4K |
At each fiscal year end
Single quarter
Net margin, TTM
-83.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HCWB
| FY Dec 2025 | n/a |
| FY Dec 2024 | -1,170% |
| FY Dec 2023 | -879.5% |
| FY Dec 2022 | -221.7% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | +53.1% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -854.4% |
| Sep 2024 | -915.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$12.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HCWB
| FY Dec 2025 | -$13.4M |
| FY Dec 2024 | -$14.5M |
| FY Dec 2023 | -$28.7M |
| FY Dec 2022 | -$20.7M |
| FY Dec 2021 | -$11.0M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$3.4M |
| Sep 2025 | -$3.2M |
| Jun 2025 | -$3.3M |
| Mar 2025 | -$3.5M |
| Dec 2024 | -$2.9M |
| Sep 2024 | -$3.0M |
At each fiscal year end
Single quarter
Debt to equity
0.88x
long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Debt to equity HCWB
| FY Dec 2025 | 2.46x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.47x |
| FY Dec 2022 | 0.17x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.88x |
| Mar 2026 | 1.14x |
| Dec 2025 | 2.46x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.85x
TTM operating cash flow over long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30
Cash flow to debt HCWB
| FY Dec 2025 | -1.97x |
| FY Dec 2024 | -1.04x |
| FY Dec 2023 | -3.57x |
| FY Dec 2022 | -1.62x |
| FY Dec 2021 | n/a |
| Jun 2026 | -1.85x |
| Mar 2026 | -1.74x |
| Dec 2025 | -1.97x |
| Sep 2025 | -1.89x |
| Jun 2025 | -1.85x |
| Mar 2025 | -1.01x |
| Dec 2024 | -1.04x |
| Sep 2024 | -1.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-151.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HCWB
| FY Dec 2025 | n/a |
| FY Dec 2024 | -897.4% |
| FY Dec 2023 | -98.2% |
| FY Dec 2022 | -33.6% |
| FY Dec 2021 | -74.6% |
| Jun 2026 | -151.4% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -27,726% |
| Dec 2024 | -897.4% |
| Sep 2024 | -537.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-20.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HCWB
| FY Dec 2025 | -29.1% |
| FY Dec 2024 | -102.2% |
| FY Dec 2023 | -66.4% |
| FY Dec 2022 | -29.7% |
| FY Dec 2021 | -37.3% |
| Jun 2026 | -20.1% |
| Mar 2026 | -8.5% |
| Dec 2025 | -29.1% |
| Sep 2025 | -46.4% |
| Jun 2025 | -40.9% |
| Mar 2025 | -87.3% |
| Dec 2024 | -102.2% |
| Sep 2024 | -120.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital HCWB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-150.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed HCWB
| FY Dec 2025 | -648.7% |
| FY Dec 2024 | -289.2% |
| FY Dec 2023 | -80.8% |
| FY Dec 2022 | -31.7% |
| FY Dec 2021 | -40.8% |
| Jun 2026 | -150.9% |
| Mar 2026 | -244.6% |
| Dec 2025 | -648.7% |
| Sep 2025 | n/a |
| Jun 2025 | -432.9% |
| Mar 2025 | -296.2% |
| Dec 2024 | -289.2% |
| Sep 2024 | -277.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HCWB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$7.8M
market value at close 2026-10-26 on 2026-08-14 shares, plus long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30, minus cash 2026-06-30
Enterprise value HCWB
| FY Dec 2025 | $20.6M |
| FY Dec 2024 | $4.1B |
| FY Dec 2023 | $10.6B |
| FY Dec 2022 | $16.5B |
| FY Dec 2021 | $19.9B |
| Jun 2026 | $39.4M |
| Mar 2026 | $19.9M |
| Dec 2025 | $20.6M |
| Sep 2025 | $53.5M |
| Jun 2025 | $38.6M |
| Mar 2025 | $3.1B |
| Dec 2024 | $4.1B |
| Sep 2024 | $4.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-600.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield HCWB
| FY Dec 2025 | -85.1% |
| FY Dec 2024 | -0.4% |
| FY Dec 2023 | -0.3% |
| FY Dec 2022 | -0.1% |
| FY Dec 2021 | -0.1% |
| Jun 2026 | -36.1% |
| Mar 2026 | -78.7% |
| Dec 2025 | -85.1% |
| Sep 2025 | -27.2% |
| Jun 2025 | -37.1% |
| Mar 2025 | -0.5% |
| Dec 2024 | -0.4% |
| Sep 2024 | -0.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HCWB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $54.2K | $2.6M | $2.8M | $6.7M |
| Gross profit | $10.8K | $959.4K | $560.4K | $2.6M |
| Operating income | -$13.2M | -$29.5M | -$25.7M | -$15.1M |
| Net income | -$8.0M | -$30.0M | -$25.0M | -$14.9M |
| EPS (diluted) | -10.63 | -30.96 | -0.70 | -0.42 |
| Operating cash flow | -$13.4M | -$14.2M | -$22.5M | -$10.4M |
| Cash | $2.0M | $4.7M | $3.6M | $22.3M |
| Long-term debt | $0 | $7.4M | $6.3M | $6.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
HCWB Stock Sonar score 6/7 axes
Find similar shapesCompareHCWB ranks highest on insider conviction (89th percentile) and risk and compliance (55th), and lowest on institutional and government (5th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HCWB filings, in plain words
Are HCW Biologics insiders buying or selling HCWB?
In the 180 days to 2026-10-28, HCW Biologics insiders were net buyers, a net $531.5K across purchases and sales reported on Form 4, by 4 buyers.
Read the full summary
In the 180 days to 2026-10-28, HCW Biologics insiders were net buyers of HCWB, a net $531.5K across purchases and sales reported on Form 4 by 4 buyers. 4 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
